Zdrowie i gospodarka · 09/05/2025

FDA Classifies DNA-Based Test for Hematological Malignancies into Class II with Special Controls

The FDA has classified a DNA-based test to measure minimal residual disease in hematological malignancies into Class II with special controls, aiming to ensure safety and effectiveness while reducing regulatory burdens and enhancing patient access to innovative devices.